Immunotherapy combined with chemotherapy for lung cancer after failure of targeted therapy

Targeted therapy for lung cancer is one of the important means for the treatment of lung cancer, but some patients have failed in the treatment, which has brought heavy psychological and economic burden to patients and their families, and also brought difficulties to doctors in the treatment. In response to this situation, immune combination chemotherapy has become a new treatment option, bringing new hope for patients who have failed in targeted therapy. 1. Causes and difficulties of failure of targeted therapy for lung cancer Lung cancer is a common malignant tumor. Targeted therapy is one of the important means of lung cancer treatment, but some patients have failed in treatment. The main reasons for the failure of targeted therapy include drug resistance of tumors, drug resistance caused by gene mutation and improper choice of treatment options. The failure of targeted therapy brings heavy psychological and economic burden to patients and their families, and also brings treatment dilemma to doctors. In response to this situation, immune combination chemotherapy has become a new treatment option, bringing new hope for patients who have failed in targeted therapy. 2. The principle of immunotherapy combined with chemotherapy and the principle of superior immunotherapy: immunotherapy is to use the patient’s own immune system to prevent or inhibit the growth and spread of tumors. Advantages of immune combination chemotherapy: Immune combination chemotherapy is a combination of immunotherapy and chemotherapy, which enhances the effect of chemotherapy by activating the patient’s own immune system. Compared with single chemotherapy or immunotherapy, immune combination chemotherapy has the following advantages: 1. Enhanced therapeutic effect: Immune combination chemotherapy can promote the apoptosis of tumor cells and enhance the efficacy of chemotherapy drugs. 2. 2. Reduce toxic and side effects: Due to the activation of the patient’s own immune system, immune combination chemotherapy can reduce the occurrence of toxic and side effects compared with single chemotherapy dose. 3. Prolonged survival: Some studies have shown that immunotherapy combined with chemotherapy can significantly prolong the survival of lung cancer patients. Therefore, immunotherapy combined with chemotherapy, as a new treatment method, is of great significance for some patients with lung cancer. 3. In recent years, a series of breakthroughs have been made in the research of immunotherapy combined with chemotherapy for lung cancer. Clinical trial data show that immunotherapy combined with chemotherapy can not only significantly improve the survival rate of patients, but also reduce the risk of tumor progression and metastasis. Studies have shown that the combination of PD-L1 inhibitors and chemotherapy can effectively activate the patient’s own immune system and improve the killing effect of immune cells on tumors. At the same time, targeted therapeutic drugs for different gene mutations also play an active role in immunotherapy. These research results have brought new hope to lung cancer patients, which has given new treatment options to patients who were desperate for the failure of targeted therapy. However, immunotherapy combined with chemotherapy is not suitable for all patients, and individualized treatment must be formulated according to clinical and molecular characteristics. 4. Treatment indications and side effects management In the treatment of lung cancer with immunotherapy, the choice of indications is very important. Doctors will determine the indications of treatment according to the specific conditions of patients and the stage of disease development, including the type, stage and gene mutation of tumors. At the same time, in view of the possible side effects of immune combined chemotherapy, patients and their families need to pay close attention to and actively cooperate with the management of doctors. Common side effects include rash, fatigue, nausea and diarrhea caused by excessive immune response, as well as hair loss, anemia and thrombocytopenia caused by chemotherapy. In the course of treatment, patients should maintain a good mentality, actively cooperate with doctors in the management of side effects, timely medical treatment, and comply with medical supervision. For any discomfort in the course of treatment, patients should seek medical treatment in time to avoid self-withdrawal or dosage adjustment. During treatment, patients need to pay attention to diet, moderate exercise, adequate sleep, and actively cooperate with family support and care to reduce the negative effects of side effects and improve the therapeutic effect and quality of life. 5. Potential and precautions of treatment regimens The potential of treatment regimens lies in that immunotherapy combined with chemotherapy can improve the therapeutic effect of lung cancer patients and prolong their survival. Immunotherapy can activate the patient’s own immune system, help the body’s immune cells to recognize and attack cancer cells, while combined chemotherapy can reduce the tumor load, synergistic effect can enhance the efficacy. However, patients and families need to take care to avoid infection when performing immune combination chemotherapy, because the suppressed immune system may increase the risk of infection. In addition, patients should avoid exposure to the source of disease infection and live vaccines during immunotherapy. In addition, patients need to maintain good nutritional status and proper rest during treatment, actively cooperate with the doctor’s treatment plan, regularly review and monitor the treatment response and side effects, in order to improve the treatment effect and protect the quality of life of patients. 6. Diagnosis and monitoring of patients with failure of targeted therapy For patients with lung cancer who have failed targeted therapy, diagnosis and monitoring are crucial. Clinically, we will diagnose and monitor by means of regular imaging examination, blood marker detection and symptom observation. Imaging examinations include CT, MRI, PET-CT and so on, among which PET-CT has high sensitivity in screening tumor metastasis and recurrence. Detection of blood markers can help us understand the growth of tumors and the degree of cell mutation. In addition, the patient’s own symptoms and physical condition are also important reference factors for diagnosis and monitoring. Doctors will adjust the treatment plan in time according to these information, improve the treatment effect, monitor the patient’s physical reaction and psychological state, and give necessary support and help.